Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Driehaus Capital Management LLC

Driehaus Capital Management LLC lowered its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 23.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 339,698 shares of the company's stock after selling 105,654 shares during the quarter. Driehaus Capital Management LLC owned approximately 0.57% of Protagonist Therapeutics worth $13,112,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. FNY Investment Advisers LLC acquired a new stake in Protagonist Therapeutics during the fourth quarter worth approximately $38,000. Covestor Ltd raised its holdings in Protagonist Therapeutics by 5,200.0% during the fourth quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after purchasing an additional 1,612 shares in the last quarter. KBC Group NV raised its holdings in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after purchasing an additional 737 shares in the last quarter. New Vernon Capital Holdings II LLC acquired a new stake in Protagonist Therapeutics during the fourth quarter worth approximately $118,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after acquiring an additional 295 shares during the period. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Transactions at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction dated Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total value of $80,776.00. Following the completion of the transaction, the chief financial officer now owns 61,065 shares of the company's stock, valued at approximately $2,808,990. The trade was a 2.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Arturo Md Molina sold 30,514 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total transaction of $1,700,850.36. Following the completion of the transaction, the insider now directly owns 83,892 shares of the company's stock, valued at $4,676,140.08. The trade was a 26.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,532 shares of company stock valued at $3,665,786 in the last 90 days. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on PTGX shares. The Goldman Sachs Group cut their target price on shares of Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a report on Monday, February 24th. JMP Securities reaffirmed a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a report on Friday, February 7th. BMO Capital Markets lifted their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $65.44.

Protagonist Therapeutics Price Performance

Shares of NASDAQ PTGX traded up $0.89 during trading on Thursday, hitting $44.66. 202,205 shares of the company were exchanged, compared to its average volume of 872,445. The company has a market cap of $2.77 billion, a price-to-earnings ratio of 16.79 and a beta of 2.65. Protagonist Therapeutics, Inc. has a 1 year low of $27.00 and a 1 year high of $60.60. The firm's fifty day moving average price is $47.30 and its 200 day moving average price is $42.68.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.31. The company had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.